NEW DIRECTIONS IN PAIN RESEARCH: I Release Date: September 4, 1998 PA NUMBER: PA-98-102 P.T. National Institute of Neurological Disorders and Stroke National Institute of Dental Research National Cancer Institute National Institute on Aging National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute on Deafness and Other Communication Disorders National Institute on Drug Abuse National Institute of General Medical Sciences National Institute of Nursing Research Office of Research on Women's Health PURPOSE The National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Dental Research (NIDR), serving as the lead Institutes for the National Institutes of Health (NIH) Pain Research Consortium, together with the National Cancer Institute (NCI), National Institute on Aging (NIA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Drug Abuse (NIDA), National Institute of General Medical Sciences (NIGMS), National Institute of Nursing Research (NINR), and the Office of Research on Women's Health (ORWH), encourage investigator-initiated research project grant applications to study mechanisms underlying analgesic response and pain to advance the development of novel pain interventions, treatments and management strategies. The purpose of this New Directions in Pain Research: I program announcement (PA) is to inform the scientific community of broad, shared interests in pain research encompassing the various components of the NIH, and to stimulate and foster a wide range of basic, translational and patient-oriented clinical studies on pain. Applications are particularly encouraged to study pain throughout the lifespan from the perspectives of molecular genetics, transcriptional controls, signal transduction, including cellular/molecular mechanisms, innovative imaging technologies, plasticity and from hormonal or gender influences. The pain experience needs to be examined at all levels of analysis from the gene, molecule, cell, tissue, and organ, to the individual, family and community, with the ultimate goal of developing new insights into pain intervention, treatment and management. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, New Directions in Pain Research: I, is related to the priority areas of chronic disabling conditions, cancer, and clinical prevention services. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017- 001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and non- profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. MECHANISM OF SUPPORT The mechanism of support will be the research project grant (R01). Applicants are strongly encouraged to contact the program official listed under INQUIRIES for information. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. Awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement (April 1, 1994). RESEARCH OBJECTIVES Background Pain is a significant national health problem. It is the most common reason individuals seek medical care, with millions of medical visits annually; costing the American public more than $100 billion each year in health care, compensation and litigation. Some studies suggest that more than a third of the American population suffers from a chronic pain condition at some point in their life. Pain-related disability presents a significant and costly liability to workers, employers and society. In the workplace, a significant proportion of employees, about 14%, take time off from their jobs due to pain conditions. In hospitalized patients, pain has been associated with increased length of stay, longer recovery time, and poorer patient outcomes, all of which have health care quality and cost implications. Pain, therefore, has a profound impact on the quality of life and health-associated costs for all Americans. Significant progress is being made in understanding the neurobiology of pain. New approaches to more effective diagnostic tools as well as treatment and management strategies, offer unique scientific challenges. Individuals during development and aging, may react in very different ways to pain, perhaps due to the influence of genetic differences, gender, hormones, and/or past experiences. Thus, pain needs to be studied at all levels of basic and clinical research, including the gene, molecule, cell, tissue, and organ, and individual, with the ultimate goal of developing innovative approaches to intervention and management of pain. In order to develop a Trans-NIH research agenda, NIH sponsored a major Symposium: "New Directions in Pain Research," in November 1997. This meeting, under the aegis of the NIH Pain Research Consortium, resulted in the identification of research needs reflecting recommendations from a broad spectrum of the scientific community expert in pain and non-pain research. Scope of Research Sought Basic, translational, and patient-oriented clinical research on pain is solicited through this program announcement. The areas in which pain research is encouraged cuts across the interests and missions of many NIH Institutes, Offices, Centers and programs. Applications should not be limited to theses topics or viewed as restricted to only one specific Institute, Office or Center. Current NIH referral guidelines will be used to assign grant applications to the most appropriate NIH Institute based on the scientific focus of the application. The following examples are provided as topics falling within the scope of this program announcement. These examples are presented illustratively, are not exclusive, and are not presented in any particular priority order. o Investigation of the genetic contribution of differences in pain response, perception and modulation, using tools such as quantitative trait locus analysis for identifying genes that contribute to complex traits and diseases, such as pain. o Development of new model systems of the molecular genetics of pain transmission, modulation and perception, that would include individual and multiple gene mapping, transgenic animal models, and studies of individual and multiple gene expression. o Exploration of the neuromolecular basis of pain, by investigating targets in signal transduction pathways, e.g., calcium, potassium or sodium ion channels, that may be the most effective points for drug development and intervention. o Exploration of the role of second messenger systems, including G protein- coupled receptors and protein kinases, in pain transmission and modulation. o Expansion of research on neuroimaging of pain, including analytical techniques for the study of structural and functional correlates of pain perception, particularly for diagnostic purposes. o Research on neuroplastic processes as these relate to the development and persistence of chronic pain conditions. o Mechanisms underlying differences in pain and analgesic response due to hormonal or gender-related factors. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research", which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513), and in the NIH GUIDE FOR GRANTS AND CONTRACTS of March 18, 1994, Volume 23, Number 11. Investigators may obtain copies from these sources or from the program staff or contact person listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. NIH POLICY AND GUIDELINES ON THE INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are specific and ethical reasons not to include them. This policy applies to all initial (Type 1) applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects" that was published in the NIH Guide for Grants and Contracts, March 6, 1998, and is available at the following URL address: http://www.nih.gov/grants/guide/notice-files/not98-024.html APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95) and will be accepted at the standard application deadlines as indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, telephone (301) 710-0267; Email: [email protected]. The title and number of the PA must be typed in Section 2 on the face page of the application. The completed original application and five legible copies must be sent or delivered to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) REVIEW CONSIDERATIONS Applications will be assigned on the basis of established PHS referral guidelines. Applications that are complete will be evaluated for scientific and technical merit by an appropriate peer review group convened in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council or board. Review Criteria The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. In the written review, comments on the following aspects of the application will be made in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered in the assignment of the overall score. (1) Significance. Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? (2) Approach. Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? (3) Innovation. Does the project employ novel concepts, approaches or method? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? (4) Investigator. Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? (5) Environment. Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? The initial review group will also examine the provisions for the protection of human and animal subjects and the safety of the research environment. AWARD CRITERIA Applications will compete for available funds with all other approved applications assigned to that institute/center (IC). The following will be considered in making funding decisions: quality of the proposed project as determined by peer review, availability of funds, and program priority. INQUIRIES Inquiries concerning this program announcement are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Dr. Cheryl A. Kitt Division of Convulsive, Infectious and Immune Disorders National Institute of Neurological Disorders and Stroke Federal Building, Room 504 Bethesda, MD 20892 Telephone: (301) 496-1431 FAX: (301) 402-2060 Email: [email protected] Dr. Patricia Bryant Temporomandibular Joint Disorders and Neuropathies and Neurodegenerative Diseases National Institute of Dental Research 45 Center Drive, Room 4AN-24E Bethesda, MD 20892-6402 Telephone: (301) 594-2095 FAX: (301) 480-8318 Email: [email protected] Claudette Varricchio, DSN, FAAN Division of Cancer Prevention National Cancer Institute 6130 Executive Boulevard, Room 300 Bethesda, MD 20892-7340 Telephone: (301) 496-8541 FAX: (301) 496-8667 Email: [email protected] Judith A. Finkelstein, Ph.D. Neuroscience and Neuropsychology of Aging Programs National Institute on Aging 7201 Wisconsin Avenue, Suite 3C307 - MSC 9205 Bethesda, MD 20892-9205 Telephone: (301) 496-9350 FAX: (301) 496-1494 Email: [email protected] John Y. Killen, M.D. Division of Acquired Immunodeficiency Syndrome National Institute of Allergy and Infectious Diseases 6003 Executive Boulevard, Room 2A18 Rockville, MD 20892-7620 Telephone: (301) 496-0545 FAX: (301) 402-1505 Email: [email protected] James S. Panagis, M.D., M.P.H. Orthopaedics Program National Institute of Arthritis and Musculoskeletal and Skin Diseases 45 Center Drive, Room 5AS-37K, MSC 4500 Bethesda, MD 20892-6500 Telephone: (301) 594-5055 FAX: (301) 480-4543 Email: [email protected] Rochelle Small, Ph.D. Division of Human Communication National Institute on Deafness and Other Communication Disorders 6120 Executive Boulevard, Room 400C MSC 7180 Bethesda, MD 20892-7180 Telephone: (301) 402-3464 FAX: (301) 402-6251 Email: [email protected] David A. Thomas, Ph.D. Division of Basic Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A-19 Rockville, MD 20857 Telephone: (301) 443-6975 Email: [email protected] Alison E. Cole, Ph.D. Division of Pharmacology, Physiology, and Biological Chemistry National Institute of General Medical Sciences 45 Center Drive, Room 2AS.49K, MSC 6200 Bethesda, MD 20892-6200 Telephone: (301) 594-1826 FAX: (301) 480-2802 Email: [email protected] Mary D. Leveck, Ph.D., RN Program Director National Institute of Nursing Research Building 45, Room 3AN-12 Bethesda, MD 20892-6300 Telephone: (301) 594-5963 FAX: (301) 480-8260 Email: [email protected] Joyce Rudick Office of Research on Women's Health National Institutes of Health Building One, Room 201 Bethesda, MD 20892 Telephone: (301) 402-1770 FAX: (301) 402-1798 Email: [email protected] Direct inquiries regarding fiscal matters to: Karen D. Shields Grants Management Branch National Institute of Neurological Disorders and Stroke Federal Building, Room 1004 Bethesda, MD 20892 Telephone: (301) 496-9231 Email: [email protected] Mr. Martin R. Rubinstein Division of Extramural Research National Institute of Dental Research Natcher Building, Room 4AN-44A 45 Center Drive, MSC 6402 Bethesda, MD 20892-6402 Telephone: (301) 594-4800 FAX: (301) 480-8301 email: [email protected] William G Wells Grants Administration Branch National Cancer Institute Executive Plaza South, Room 243 Bethesda, MD 20892 Telephone: (301) 496-7800, ext. 250 FAX: (301) 496-8601 Email: [email protected] Joseph Ellis Grants Management Officer National Institute on Aging Gateway Building, Suite 2N12 Bethesda, MD 20892-9205 Telephone: (301) 496-1472 Email: [email protected] Vicki Maurer Grants Management Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases 45 Center Drive, Room 5AS-49A, MSC 4500 Bethesda, MD 20892-6500 Telephone: (301) 594-3535 FAX: (301) 480-5450 Email: [email protected] Ms. Sharon Hunt Division of Extramural Activities National Institute on Deafness and Other Communication Disorders 6120 Executive Boulevard, Room 400B, MSC 7180 Bethesda, MD 20892-7170 Telephone: (301) 402-0909 FAX: (301) 402-1757 Email: [email protected] Gary Fleming, JD, M.A. Grants Management Branch National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 Telephone: (301) 443-6710 FAX: (301) 594-6847 Email: [email protected] Ms. Toni Holland Grants Management Office National Institute of General Medical Sciences 45 Center Drive, Room 2AN-50B, MSC 6200 Bethesda, MD 20892-6200 Telephone: (301) 594-5132 FAX: (301) 480-2554 Email: [email protected] Jeff Carow Grants Management Officer National Institute of Nursing Research 6300 Center Drive, Room 3AN-12, MSC 6301 Bethesda, MD 20892-6301 Telephone: (301) 594-6869 FAX: (301) 480-8260 Email: [email protected] AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Nos. 93.131, 93.279, 93.846, 93.853, and 93.854. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||